PUBLICATION
Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish
- Authors
- Chen, H., Lei, P., Ji, H., Ma, J., Fang, Y., Yu, H., Du, J., Qu, L., Yang, Q., Luo, L., Zhang, K., Wu, W., Jin, L., Sun, D.
- ID
- ZDB-PUB-230721-47
- Date
- 2023
- Source
- Life sciences 329: 121956 (Journal)
- Registered Authors
- Keywords
- Bacterial ghosts, Drug delivery system, Escherichia coli Nissle 1917, Inflammatory bowel disease, Zebrafish
- MeSH Terms
-
- Zebrafish
- Inflammatory Bowel Diseases*/drug therapy
- Humans
- Animals
- Probiotics*
- PubMed
- 37473802 Full text @ Life Sci.
Abstract
Escherichia coli Nissle 1917 (EcN) has become a research hotspot in inflammatory bowel disease (IBD). It has a strong targeting effect on the colon, and has some therapeutic effect on inflammatory bowel disease. EcN is prepared into EcN ghosts, which also retain EcN's biological characteristics. Consequently, EcN ghosts are used for drug delivery. This study evaluated the safety and efficacy of EcN ghosts as carriers of drugs for treating IBD in zebrafish. Caco-2 cell adhesion experiments and zebrafish intestinal adhesion experiments demonstrated that EcN ghosts was highly adherent to the intestine. Additionally, oral administration of EcN ghosts attenuated dextran sulfate sodium-induced IBD symptoms by inhibiting neutrophil chemotaxis and reactive oxygen species production in larval zebrafish. Because of the unique biological functions of EcN ghosts, it may serve as a strategy for future targeted drug delivery in IBD treatment.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping